Analysts' Opinions Are Mixed on These Healthcare Stocks: CVS Health (CVS), Insulet (PODD) and Artivion (AORT)
Oppenheimer Reaffirms Their Buy Rating on Artivion (AORT)
Artivion Analyst Ratings
Oppenheimer Adjusts Artivion Price Target to $30 From $25, Maintains Outperform Rating
Artivion's Robust Financial Performance and Growth Prospects Justify Buy Rating
Lake Street Maintains Artivion(AORT.US) With Buy Rating, Maintains Target Price $30
Lake Street Maintains Artivion(AORT.US) With Buy Rating, Maintains Target Price $30
Lake Street Sticks to Their Buy Rating for Artivion (AORT)
Artivion Analyst Ratings
Artivion's Strong Market Position and Revised Endospan Deal Justify a Buy Rating and Increased Price Target
Oppenheimer Sticks to Its Buy Rating for Artivion (AORT)
Artivion: Strong Q1 Performance and Raised Guidance Validate Buy Rating
Artivion Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Lineage Therap (LCTX), Axonics Modulation Technologies (AXNX) and Artivion (AORT)
Artivion Analyst Ratings
Artivion's Growth Trajectory: A Buy Rating Amidst Promising Aortic Products and Financial Upswing
Stifel Nicolaus Remains a Buy on Artivion (AORT)
Oppenheimer Sticks to Its Buy Rating for Artivion (AORT)
Artivion Secures Buy Rating: Strong Financials and Growth Trajectory Propel Price Target Increase
Artivion Analyst Ratings
No Data